ReviewBreast cancer research : BCR2008
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance.
Review in Breast cancer research : BCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 85 citations in OpenAlex.
- CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study.Breast cancer research and treatment · 2021Trial
- Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer.Molecular oncology · 2013Trial
- Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients.PloS one · 2013Trial
- Enter sandman: how to tackle dormant breast cancer cells.Medical oncology (Northwood, London, England) · 2025Review
- Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors.Cancer metastasis reviews · 2023Review
- Prospective Monitoring of Circulating Epithelial Tumor Cells (CETC) Reveals Changes in Gene Expression during Adjuvant Radiotherapy of Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2021Article
- Article
- Utility of urinary ctDNA to monitoring minimal residual disease in early breast cancer patients.Cancer biomarkers : section A of Disease markers · 2020Article
- Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.Breast cancer research and treatment · 2019Article
- Article
- Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer.BMC cancer · 2018Article
- St. John's Wort Regulates Proliferation and Apoptosis in MCF-7 Human Breast Cancer Cells by Inhibiting AMPK/mTOR and Activating the Mitochondrial Pathway.International journal of molecular sciences · 2018Article
- Rapid and Sensitive Detection of Breast Cancer Cells in Patient Blood with Nuclease-Activated Probe Technology.Molecular therapy. Nucleic acids · 2017Article
- Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.International journal of molecular sciences · 2017Article
- Analysis of circulating tumor cells from lung cancer patients with multiple biomarkers using high-performance size-based microfluidic chip.Oncotarget · 2017Article
- Detection of Circulating Tumor Cells in Breast Cancer Patients Using Cytokeratin-19 Real-Time RT-PCR.Yonsei medical journal · 2017Article
- Microfluidics cell sample preparation for analysis: Advances in efficient cell enrichment and precise single cell capture.Biomicrofluidics · 2017Review
- Phosphorylation of serine 367 of FOXC2 by p38 regulates ZEB1 and breast cancer metastasis, without impacting primary tumor growth.Oncogene · 2016Article
- Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells.Clinical & experimental metastasis · 2016Review
- New insights into tumor dormancy: Targeting DNA repair pathways.World journal of clinical oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunocytochemical or molecular assays allow the detection of single disseminated tumor cells (DTCs) in the bone marrow (BM) or the peripheral blood in 10% to 60% of breast cancer patients without signs of metastasis. Results from recently reported studies suggest that circulating tumor cell (CTC) levels may serve as a prognostic marker and be used for early assessment of therapeutic response in patients with metastatic breast cancer. In early stage breast cancer, however, the impact of CTCs is less well established than that of DTCs in BM, where several clinical studies demonstrated that such cells are an independent prognostic factor at primary diagnosis. The characterization of DTCs/CTCs has already shed new light on the complex process underlying early tumor cell dissemination and metastatic progression in cancer patients. Characterization of DTCs should help to identify novel targets for biological therapies aimed to prevent metastatic relapse. In addition, understanding tumor 'dormancy' and identifying metastatic stem cells might result in the development of new therapeutic concepts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.